03/05/2026
GLP-1 medications and fertility are getting a lot of attention right now.
Some patients have conceived after weight loss on GLP-1 receptor agonists, often called “Ozempic Babies.” But what does the science say?
GLP-1s were developed to improve glycemic control and reduce cardiometabolic risk. In patients with obesity or insulin resistance, metabolic dysfunction can impair reproductive physiology and is associated with anovulation, hyperandrogenism, inflammation, altered endometrial receptivity, and reduced s***m parameters.
Weight loss and improved insulin sensitivity may restore ovulation in some patients, especially those with PCOS. This does not mean GLP-1s directly stimulate fertility. It means that addressing metabolic dysfunction may remove a barrier to ovulation.
Safety and timing matter. GLP-1 medications are not recommended during pregnancy due to limited human data and animal studies showing fetal risk. Most guidelines advise stopping them two months before trying to conceive.
If you are freezing eggs, discontinue GLP-1s when starting stimulation medications due to anesthesia risk. These medications delay gastric emptying, which may increase aspiration risk during sedation. This is a procedural safety issue, not an ovarian toxicity concern.
At Collab Fertility, we take a data-driven approach, evaluating metabolic health, ovarian reserve, s***m parameters, inflammation, and reproductive timeline before making recommendations.
The question is not whether GLP-1s are good or bad. It is how they fit into your timeline, metabolic profile, and reproductive goals.
If you are using or considering a GLP-1 and planning pregnancy or egg freezing, schedule a consultation to build a science-based, individualized plan.